HUP0401569A2 - Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra - Google Patents

Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra

Info

Publication number
HUP0401569A2
HUP0401569A2 HU0401569A HUP0401569A HUP0401569A2 HU P0401569 A2 HUP0401569 A2 HU P0401569A2 HU 0401569 A HU0401569 A HU 0401569A HU P0401569 A HUP0401569 A HU P0401569A HU P0401569 A2 HUP0401569 A2 HU P0401569A2
Authority
HU
Hungary
Prior art keywords
preparation
components
amlodipine
atorvastatin
carrier
Prior art date
Application number
HU0401569A
Other languages
English (en)
Inventor
Laman Alani
Sadath Ulla Khan
Thomas Michael Macneil
Nouman Abdul-Hussain Muhammad
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HUP0401569A2 publication Critical patent/HUP0401569A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

A találmány tárgya gyógyászati készítmény, amely két komponensbőltevődik össze: (a) az egyik komponens atorvastatin vagy gyógyászatiszempontból elfogadható sói granulumait és hordozóanyagot tartalmaz, ahordozóanyagok közé értve egy lúgosítószert, amely a pH-értékét 5 föléemeli; és (b) egy második komponenst, amely amlodipint vagygyógyászati szempontból elfogadható sóit tartalmazza és egyhordozóanyagot, kizárva a pH 5 fölé való emelésére szolgálólúgosítószereket, és a két komponens egy végső szilárd dózisformájúkészítménnyé formált. A találmány tárgyát képezi továbbá a fentikészítmény előállítása, a fenti készítményt tartalmazó kit, valaminteljárás angina pektorisz, ateroszklerózis, egyidejűleg fennálló magasvérnyomás és hiperlipidémia és/vagy hiperkoleszterinémia kezelésére,valamint szívrizikó tüneteinek kezelésére a gyógyászati készítményterápiásan hatásos mennyiségével. Ó
HU0401569A 2001-07-31 2002-07-29 Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra HUP0401569A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (en) 2001-07-31 2002-07-29 Pharmaceutical compositions of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
HUP0401569A2 true HUP0401569A2 (hu) 2004-12-28

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401569A HUP0401569A2 (hu) 2001-07-31 2002-07-29 Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra

Country Status (46)

Country Link
US (2) US20030114497A1 (hu)
EP (2) EP1852116A1 (hu)
JP (3) JP4020863B2 (hu)
KR (2) KR100674762B1 (hu)
CN (2) CN101185646A (hu)
AP (1) AP1745A (hu)
AR (1) AR034925A1 (hu)
AT (1) ATE385793T1 (hu)
AU (1) AU2002355680B2 (hu)
BR (1) BR0211548A (hu)
CA (1) CA2444554C (hu)
CO (1) CO5540287A2 (hu)
CR (1) CR7219A (hu)
CY (1) CY1107245T1 (hu)
DE (1) DE60225014T2 (hu)
DK (1) DK1411923T3 (hu)
DO (1) DOP2002000445A (hu)
EA (1) EA006998B1 (hu)
EC (1) ECSP044965A (hu)
ES (1) ES2298381T3 (hu)
GE (1) GEP20063926B (hu)
GT (1) GT200200158A (hu)
HN (1) HN2002000198A (hu)
HR (1) HRP20040067A2 (hu)
HU (1) HUP0401569A2 (hu)
IL (1) IL159440A0 (hu)
IS (1) IS7089A (hu)
MA (1) MA27052A1 (hu)
MX (1) MXPA04000270A (hu)
MY (1) MY137519A (hu)
NI (1) NI200200095A (hu)
NO (1) NO20040405L (hu)
NZ (1) NZ530247A (hu)
OA (1) OA13300A (hu)
PA (1) PA8551701A1 (hu)
PE (1) PE20030324A1 (hu)
PL (1) PL368519A1 (hu)
PT (1) PT1411923E (hu)
RS (1) RS5304A (hu)
SG (1) SG143982A1 (hu)
SV (1) SV2003001189A (hu)
TN (1) TNSN04022A1 (hu)
UA (1) UA79750C2 (hu)
UY (1) UY27402A1 (hu)
WO (1) WO2003011283A1 (hu)
ZA (1) ZA200400659B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
EP1771455B1 (en) 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
ES2263407T1 (es) 2004-09-28 2006-12-16 Teva Pharmaceutical Industries Ltd Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas.
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
BRPI0607791A2 (pt) * 2005-03-15 2010-03-23 Lupin Ltd composiÇÕes farmacÊuticas de amlodipina e benazepril
CA2645281A1 (en) * 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (en) * 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
WO2009116061A2 (en) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Stable oral pharmaceutical composition comprising atorvastatin
SI2165702T1 (sl) 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
EP2575757A1 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
WO2013031729A1 (ja) 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
CA2296726C (en) * 1997-08-29 2004-06-29 Pfizer Products Inc. Combination therapy
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CA2303864A1 (en) * 1997-11-25 1999-06-03 Warner-Lambert Company Inhibition of lipoprotein oxidation
AU4647000A (en) * 1999-04-23 2000-11-10 R. Preston Mason Synergistic effects of amlodipine and atorvastatin
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release

Also Published As

Publication number Publication date
JP2005501051A (ja) 2005-01-13
JP4020863B2 (ja) 2007-12-12
DE60225014D1 (de) 2008-03-27
MY137519A (en) 2009-02-27
ATE385793T1 (de) 2008-03-15
CO5540287A2 (es) 2005-07-29
NO20040405L (no) 2004-03-08
EP1411923A1 (en) 2004-04-28
EP1852116A1 (en) 2007-11-07
KR100674762B1 (ko) 2007-01-25
NI200200095A (es) 2004-06-07
AP1745A (en) 2007-05-30
CY1107245T1 (el) 2012-11-21
MXPA04000270A (es) 2004-05-04
RS5304A (en) 2006-10-27
HN2002000198A (es) 2005-10-20
CN1617717A (zh) 2005-05-18
GT200200158A (es) 2003-05-15
DOP2002000445A (es) 2003-01-31
US20030114497A1 (en) 2003-06-19
CA2444554A1 (en) 2003-02-13
BR0211548A (pt) 2004-07-13
CN101185646A (zh) 2008-05-28
KR20040032148A (ko) 2004-04-14
DK1411923T3 (da) 2009-01-05
TNSN04022A1 (fr) 2006-06-01
AP2004002963A0 (en) 2004-03-31
GEP20063926B (en) 2006-09-25
DE60225014T2 (de) 2008-06-12
AU2002355680B2 (en) 2007-11-15
JP2007153908A (ja) 2007-06-21
MA27052A1 (fr) 2004-12-20
CA2444554C (en) 2007-09-04
HRP20040067A2 (en) 2005-02-28
OA13300A (en) 2007-04-13
AR034925A1 (es) 2004-03-24
ZA200400659B (en) 2005-04-28
US20050107446A1 (en) 2005-05-19
CR7219A (es) 2004-03-24
UA79750C2 (en) 2007-07-25
WO2003011283A1 (en) 2003-02-13
SG143982A1 (en) 2008-07-29
JP2007314566A (ja) 2007-12-06
NZ530247A (en) 2006-06-30
EP1411923B1 (en) 2008-02-13
IL159440A0 (en) 2004-06-01
UY27402A1 (es) 2003-02-28
SV2003001189A (es) 2003-03-18
ECSP044965A (es) 2004-03-23
EA006998B1 (ru) 2006-06-30
ES2298381T3 (es) 2008-05-16
PE20030324A1 (es) 2003-04-03
EA200400028A1 (ru) 2004-08-26
PL368519A1 (en) 2005-04-04
PT1411923E (pt) 2008-04-02
PA8551701A1 (es) 2003-02-14
IS7089A (is) 2003-12-22
KR20060054495A (ko) 2006-05-22

Similar Documents

Publication Publication Date Title
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
EP0391002A3 (en) Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid
HUP0202461A2 (hu) Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
SE9901573D0 (sv) New compounds
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
SE0102440D0 (sv) New compound
HUP0001583A2 (hu) Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
FR2869611B1 (fr) Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
SE9901572D0 (sv) New compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees